RE:It gets better...from The Chairman's Bio: see the bold type
Chairman's letter to Shareholders on Sept 14, 2016 he says:
We are excited about the progress to date and believe that the remainder of 2016 should be very interesting: our portfolio companies have made great progress, and we believe that we will have significant news to announce later in the year.
Biohaven is scheduled to begin a bioequivalence study of BHV--0223 that will allow it to begin marketing the molecule as a treatment for ALS (amyotrophic lateral sclerosis) the later part of next year.
Looking only at the orphan indications of ALS and SCA, the peak annual revenue of BHV--0223 and BHV--4157 combined would be expected to be in the few hundreds of millions each year.
Letter can be found here:
www.portagebiotech.com/images/pdf/Portage_Biotech_September_Chairman_Letter.pdf